drugset / Trial / NCT04916119
Study of IBI323 in Patients With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety, tolerability and efficacy of IBI323(anti-LAG-3/PD-L1) or in combination with chemotherapy in participants with advanced malignancies. Another purpose is to determine the pharmacokinetics,pharmacodynamics and immunogenicity of IBI323
Timeline
- Start
- 2021-06-29
- Primary completion
- 2023-06-23
- Completion
- 2023-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI323 | Unknown | 0.03 mg/kg | Intravenous |
| Subject | IBI323 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | IBI323 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | IBI323 | Unknown | 1 mg/kg | Intravenous |
| Subject | IBI323 | Unknown | 3 mg/kg | Intravenous |
| Subject | IBI323 | Unknown | 10 mg/kg | Intravenous |
| Subject | IBI323 | Unknown | 20 mg/kg | Intravenous |